Apremilast for Pediatric Patients With Moderate To Severe Plaque Psoriasis
Researchers aimed to evaluate the efficacy and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis.
Researchers aimed to evaluate the efficacy and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis.
Lawrence Eichenfield, MD, investigates the efficacy, physician satisfaction, treatment patterns, and outcomes of topical ruxolitinib, a novel therapy for atopic dermatitis, through the review of…
As 2024 comes to a close, Dermatology Times is taking a look back at the studies, treatment, and advances in chronic hand eczema this year.
According to research presented by Justin Watts, MD, at the 2024 ASH Annual Meeting & Exposition in San Diego, California, INCB057643 may improve patient outcomes…
As 2024 comes to a close, Dermatology Times is taking a look back at the studies, therapies, and advances in prurigo nodularis this year.
Interview with Lauren A. V. Orenstein, MD, MSc, author of Outpatient Dermatology Productivity Measures by Patient Race, Sex, and Age. Hosted by Adewole S. Adamson,…
This case report describes a man in his 50s with type 2 diabetes and hyperlipidemia who was admitted for rash and proximal muscle weakness, pain,…
Dermatology Times is looking back on the top stories in dermatology that involve strides in skin health equity: addressing disparities for skin of color, women,…
Renata Block, MMS, PA-C; Ted Lain, MD, MBA, FAAD; Zoe Diana Draelos, MD; and Cheri Frey, MD, FAAD, bust common skin care myths in a…
Copy: Hidradenitis suppurativa (HS) disproportionately affects women of childbearing age. As almost half of pregnancies in the United States are unplanned, dermatologists must give special…
This cohort study investigates the long-term risk of autoimmune and autoinflammatory diseases among patients in South Korea who had a COVID-19 diagnosis using an extended…